Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Single-arm, Open-label Clinical Study on the Safety and Efficacy of PID23 Injection in Treating Patients With Relapsed/Refractory Acute Leukemia

NCT07696481 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT07696481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07696481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Single-arm, Open-label Clinical Study on the Safety and Efficacy of PID23 Injection in Treating Patients With Relapsed/Refractory Acute Leukemia
Lead sponsor
Zhujiang Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
March 31, 2030
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute leukemia, relapsed or refractory acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia (aml)